KR20240008335A - 알파-시누클레인 응집체 분해용 화합물 및 이의 용도 - Google Patents

알파-시누클레인 응집체 분해용 화합물 및 이의 용도 Download PDF

Info

Publication number
KR20240008335A
KR20240008335A KR1020237042637A KR20237042637A KR20240008335A KR 20240008335 A KR20240008335 A KR 20240008335A KR 1020237042637 A KR1020237042637 A KR 1020237042637A KR 20237042637 A KR20237042637 A KR 20237042637A KR 20240008335 A KR20240008335 A KR 20240008335A
Authority
KR
South Korea
Prior art keywords
formula
compound
alkyl
substituted
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237042637A
Other languages
English (en)
Korean (ko)
Inventor
밍-쿠에이 장
폴 템페스트
이흐-시안 린
Original Assignee
아프리노이아 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아프리노이아 테라퓨틱스 리미티드 filed Critical 아프리노이아 테라퓨틱스 리미티드
Publication of KR20240008335A publication Critical patent/KR20240008335A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treating Waste Gases (AREA)
KR1020237042637A 2021-05-14 2021-05-14 알파-시누클레인 응집체 분해용 화합물 및 이의 용도 Pending KR20240008335A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/054167 WO2022238737A1 (en) 2021-05-14 2021-05-14 Compounds for degrading alpha-synuclein aggregates and uses thereof

Publications (1)

Publication Number Publication Date
KR20240008335A true KR20240008335A (ko) 2024-01-18

Family

ID=76034924

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237042637A Pending KR20240008335A (ko) 2021-05-14 2021-05-14 알파-시누클레인 응집체 분해용 화합물 및 이의 용도

Country Status (8)

Country Link
EP (1) EP4337259A1 (https=)
JP (1) JP2024517340A (https=)
KR (1) KR20240008335A (https=)
CN (1) CN117377496A (https=)
AU (1) AU2021444937A1 (https=)
CA (1) CA3218573A1 (https=)
TW (1) TW202304516A (https=)
WO (1) WO2022238737A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025162452A1 (zh) * 2024-01-29 2025-08-07 思努赛生物科技(上海)有限责任公司 一种识别α-突触核蛋白聚集体的化合物及其用途
CN118845735A (zh) * 2024-06-21 2024-10-29 合肥综合性国家科学中心大健康研究院 金刚烷衍生物在制备离子通道tmem175激动剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10300155B2 (en) * 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
ES2965049T3 (es) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
JP7297053B2 (ja) * 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
PH12022500002A1 (en) * 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof

Also Published As

Publication number Publication date
JP2024517340A (ja) 2024-04-19
CA3218573A1 (en) 2022-11-17
WO2022238737A1 (en) 2022-11-17
AU2021444937A1 (en) 2023-11-30
CN117377496A (zh) 2024-01-09
TW202304516A (zh) 2023-02-01
EP4337259A1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
US12377152B2 (en) Compounds for degrading alpha-synuclein aggregates and uses thereof
AU2017222958B2 (en) Glycosidase inhibitors
AU2017222964B2 (en) Glycosidase inhibitors
CN115697990A (zh) 基于吲唑的化合物和相关使用方法
EP3548476A1 (en) Ire1 small molecule inhibitors
DE60305037T2 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
TW201446768A (zh) S1p及/或atx調節劑
JP2023532623A (ja) ハンチントン病を処置するためのｈｔｔモジュレータ
KR20240008335A (ko) 알파-시누클레인 응집체 분해용 화합물 및 이의 용도
CA3167339A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
JP2023522078A (ja) １，５－ジヒドロ－２，４－ベンゾジアゼピン－３－オン誘導体及びその使用
AU7086900A (en) Heterocyclic ketone and thioester compounds and uses
CN114450006B (zh) TrkB正别构调节剂
JP2022533007A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）に対し活性な新規のインドリジン－２－カルボキサミド
HK40069557B (zh) 用於降解tau蛋白聚集体的化合物及其用途
HK40069557A (en) Compounds for degrading tau protein aggregates and uses thereof
JP2025533107A (ja) ラクテート増強化合物及びその使用
HK40080583A (en) 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
HK1122286A (en) Imidazolone phenylalanine derivatives as vla-4 antagonists

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902